REGN Share Price Performance
US$746.80
5.83 (0.79%)
4.4% undervalued intrinsic discount
US$781.13
Fair Value
Price US$746.80
AnalystConsensusTarget US$781.13
AnalystHighTarget US$920.77
AnalystLowTarget US$540.00
Fair ValueUS$781.13
Share Pricen/a
Regeneron Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 2 Comments on narratives written by author
- 167 Fair Values set on narratives written by author
REGN Community Narratives
AN
Fair Value US$781.13 4.4% undervalued intrinsic discount
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
2users have liked this narrative
2users have commented on this narrative
78users have followed this narrative
AN
Fair Value US$890 16.1% undervalued intrinsic discount
Dupixent And EYLEA Will Seize Expanding Global Markets
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value US$543 37.5% overvalued intrinsic discount
US Healthcare Reforms And Biosimilars Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Key Takeaways Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings. Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.Read more
2users have liked this narrative
2users have commented on this narrative
78users have followed this narrative
AN
US$781.13
4.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
7.24% p.a.
Profit Margin
30.23%
Future PE
16.26x
Price in 2028
US$949.95
Dupixent And EYLEA Will Seize Expanding Global Markets
Key Takeaways Regeneron's best-in-class therapies, strong product adoption, and innovative pipeline position it for rapid market share gains and expanded, diversified long-term growth. Strategic investments in manufacturing and advanced biologics platforms enable operational efficiency, robust supply, and capitalize on rising global demand for precision medicines.Read more
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$890
16.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
7.86% p.a.
Profit Margin
34.74%
Future PE
16.09x
Price in 2028
US$1.07k
US Healthcare Reforms And Biosimilars Will Erode Margins
Key Takeaways Reliance on a few key products and increasing biosimilar competition threaten revenue growth and earnings stability as healthcare reforms pressure pricing power. Rising R&D expenses and demographic headwinds may limit the long-term growth potential and sustainability of current revenue streams.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$543
37.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
1.38% p.a.
Profit Margin
22.52%
Future PE
18.23x
Price in 2028
US$655.26
Trending Discussion
Recently Updated Narratives
AN
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Fair Value: US$781.13 4.4% undervalued intrinsic discount
78 followersusers have followed this narrative
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Dupixent And EYLEA Will Seize Expanding Global Markets
Fair Value: US$890 16.1% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
US Healthcare Reforms And Biosimilars Will Erode Margins
Fair Value: US$543 37.5% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Regeneron Pharmaceuticals, Inc. Key Details
About REGN
- Founded
- 1988
- Employees
- 15222
- CEO
- WebsiteView website
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
